Cereblon - A new target of therapy in the treatment of multiple myeloma;Cereblon - Nový terapeutický del' v liečbe mnohopočetného myelómu

Klinicka Onkologie

Volumn 27, Issue 5, 2014, Pages 326-330

  Stankova M ^a   Besse L ^a,b   Sedlarikova, L ^a,b   Vrabel D ^a,b   Hajek R ^a,b   Sevcikove, S ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Cereblon; Immunomodulatory drugs; Multiple myeloma

Indexed keywords

CEREBLON; THALIDOMIDE; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; CRBN PROTEIN, HUMAN; CUL4A PROTEIN, HUMAN; CULLIN; IMMUNOSUPPRESSIVE AGENT; PEPTIDE HYDROLASE; UBIQUITIN PROTEIN LIGASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; GENE EXPRESSION; HUMAN; MULTIPLE MYELOMA; PROTEIN DEGRADATION; TREATMENT RESPONSE; GENETICS; METABOLISM;

CULLIN PROTEINS; GENE EXPRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; PEPTIDE HYDROLASES; THALIDOMIDE; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

EID: 84908370763     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: 10.14735/amko2014326     Document Type: Article

References (29)

1. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999;10(12):1419-1432.
2. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121(5):749-757.
3. Hájek R, Adam Z, Sčudla V et al. Diagnostika a léčba mnohočetného myelomu. Tranfuze a hematologie dnes 2012;18(Suppl 1):1-89.
4. Sedlaflková L, Kubiczková L, Ševčíkové S et al. Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res 2012;36(10):1218-1224. doi: 10.1016/j.leukres.2012.05.010.
5. Ito T, Ando H, Suzuki T et al. Identification of a primary target of thalidomide teratogenicity. Science 2010;327(5971):1345-1350. doi: 10.1126/science.1177319.
6. Ohta T, Michel JJ, Schottelius AJ et al. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol Cell 1999;3(4):535-541.
7. Shlyanov P, Nag A. Raychaudhuri P. Cullin 4A associates with the UV-damaged DNA-binding Protein DDB. J Biol Chem 1999;274(50):35309-35312.
8. Heintel D, Rocci A, Ludwig H et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 2013;161(5):695-700. doi: 10.1111/bjh.12338.
9. Broyl A, Kuiper R, van Duin M et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013;121(4):624-627. doi: 10.1 182/blood-2012-06-438101.
10. Schuster SR, Kortuem KM, Zhu YX et al. The clinical significance of cereblon expression in multiple myeloma. Leuk Res 2014;38(1):23-28. doi: 10.1016/j.leukres-2013.08.015.
11. Jo S, Lee KH, Song S et al. Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain. J Neurochem 2005;94(5):1212-1224.
12. Higgins JJ, Rosen DR, Loveless JM et al. A gene for nonsyndromic mental retardation maps to chromosome 3p25-pter. Neurology 2000;55(3):335-340.
13. Higgins JJ, Pucilowska J, Lombardi RQ et al. A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 2004;63(10):1927-1931.
14. Aizawa M, Abe Y, Ito T et al. mRN A distribution of the thalidomide binding protein cereblon in adult mouse brain. Neurosci Res 2011;69(4):343-347. doi: 10.1016/j. neures.2010.12.019.
15. Higgins JJ, Tal AL, Sun X et al. Temporal and spatial mouse brain expression of cereblon, an ionic channel regulator involved in human intelligence. J Neurogenet 2010;24(1):18-26. doi: 103109/01677060903567849.
16. Hohberger B, Enz R. Cereblon is expressed in the retina and binds to voltage-gated chloride channels. FEBS Lett 2009;583(4):633-637. doi: 10.1016/j.febslet.2009.01.018.
17. Xin W, Xiaohua N, Peilin C et al. Primary function analysis of human mental retardation related gene CRBN. Mol Biol Rep 2008;35(2):251-256.
18. Lee KM, Jo S, Kim H et al. Functional modulation of AMP-activated protein kinase by cereblon. Biochim Biophys Acta 2011;1813(3):448-455. doi: 10.1016/j. bbamcr.2011.01.005.
19. Lee KM, Lee J, Park CS. Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type 4. Biochem Biophys Res Commun 2012;427(3):618-622. doi: 10.1016/j.bbrc2012.09.108.
20. Hershko A, Heller H, Elias S et al. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem 1983;258(13):8206-8214.
21. Bedewy AM, EL-Maghraby SM. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment In multiple myeloma patients? Eur J Haematol 2014;92(1):13-18. doi: 10.1111/ejh.12207.
22. Zhu YX, Braggio E, Shi CX et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118(18):4771-4779. doi: 10.1 182/blood-2011-05-356063.
23. Gandhi AK, Mendy D, Waldman M et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol 2014;164(2):233-244. doi: 10.1111/bjh.12622.
24. Thakurta A, Gandhi AK, Waldman MF et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia 2014;28(5):1129-1131. doi: 10.1038/leui013315.
25. Egan JB, Kortuem KM, Kurdoglu A et al. Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol 2013;161(5):748-751. doi: 10.1111/bjh.12291.
26. Gandhi AK, Kang J, Havens CG et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4 (CRBN). Br J Haematol 2014;164(6):811-821. doi: 10.1111/bjh.12708.
27. Bandyopadhyay S, Duré M, Paroder M et al. Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells. Blood 2007;109(7):2878-2886.
28. Shaffer AL, Emre NC, Lamy L et al. IRF4 addiction in multiple myeloma. Nature 2008;454(7201):226-231. doi: 10.1038/nature07064.
29. Lopez-Girona A, Mendy D, Ito T et al. Cereblon is a direct protein target for Immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26(11):2326-2335. doi: 10.1038/leu.2012.119.